Amgen (AMGN) Tops Q2 EPS by 41c, Issues In-Line Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. SPY
2. PTC
3. NVDA
4. PCVX
5. META
6. USO
7. MSFT
8. AMD
9. AMZN
10. ATH

Go back to Amgen (AMGN) Tops Q2 EPS by 41c, Issues In-Line Guidance

Amgen Reports Second Quarter 2020 Financial Results

July 28, 2020 4:01 PM EDT

THOUSAND OAKS, Calif., July 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2020.

Key results include:

Despite the impact of the COVID-19 pandemic, total revenues increased 6% to $6.2 billion in comparison to the second quarter of 2019, driven by higher unit demand, offset partially by lower net selling prices. Product sales increased 6% globally, driven by 13% volume growth across a number of our newer products, including Otezla® (apremilast), MVASI® (bevacizumab-awwb), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg) and Repatha® (evolocumab), offset... More